Archive for the ‘Bioscience’ Category

Minimus Spine On Spine Blogger

Monday, October 26th, 2009

Member company Minimus Spine was recently mentioned by the highly reputable and followed blogger called The Spine Blogger.  It was a huge credibility booster for Minimus!

The post is called Ozone Therapy: Is this the Silver Bullet for Herniated Disc? Check it out!

About Minimus Spine:

Each year in the United States there are approximately one million patients that try steroid injections to relieve the pain associated with a disc herniation in their lower back.  Another 250,000 patients have exhausted non-surgical treatment and opt for surgery.  Minimus Spine believes that it can benefit these patients with a single injection and reduce the number of patients that ultimately need surgery.

We at Minimus Spine are developing ozone injection technology for spinal applications.  Ozone has been used to treat disc herniations in Europe for over 15 years and there are over 20 peer-reviewed papers documenting over 8,000 patients.  We are working to improve the existing technology and responsibly commercialize this novel therapy in the United States.  This will involve rigorous clinical trials conducted by spine surgeons and interventional radiologists.  The study will seek to confirm that an injection of ozone into a herniated disc is safe and effective.  The results of these trials will be submitted to FDA for marketing approval.  Currently, ozone cannot be legally marketed for medical application in the U.S.

This product is not yet available but efforts are being made to begin clinical trials in 2010.  Check back periodically for more information.

We hope to improve patient care and believe that we can save the health care system billions of dollars each year on unnecessary injections and surgeries.

Share and Enjoy:
  • E-mail this story to a friend!
  • Print this article!
  • Digg
  • del.icio.us
  • Facebook
  • LinkedIn
  • Twitter

ATI Bioscience Interns At Work

Thursday, October 15th, 2009

Here at ATI we have a thriving intern program!  Our interns help our member companies with everything from business plans, to research, to testing, to marketing support.

The College of Pharmacy recently did a write-up in their publication about the work some of our bioscience interns have been doing for member companies Savara and Minimus Spine.  Savara is developing drug delivery technology focused at the lung and Minimus Spine is developing non-surgical technology for disc herniation.

New companies offer insight from the start (pdf)
Grad students intern at area Pharma start-up companies

Two young startup companies developing therapies to treat medical ills may soon offer renewed promise to patients, thanks, in part, to a cooperative program with the college. This program – a collaborative effort between the college’s Drug Dynamics Institute (DDI) and Austin Technology Incubator (ATI) – has provided these early-stage ventures with pharmacy graduate student interns. In turn, these students have the unique opportunity to work closely with bioscience entrepreneurs.

Read more… (pdf).

Share and Enjoy:
  • E-mail this story to a friend!
  • Print this article!
  • Digg
  • del.icio.us
  • Facebook
  • LinkedIn
  • Twitter

ATI Launches symBIOsis

Wednesday, September 30th, 2009

The Rice Alliance-Austin Chapter has teamed up with the Bioscience program at the Austin Technology Incubator to launch symBIOsis

The term “symbiosis” is commonly used to describe close and often long-term interactions between different biological species. 

The vision for this new event – symBIOsis – will similarly provide a forum for Austin-area life sciences entrepreneurs to interact with each other, to network with each other, and to learn together about the challenges of starting and growing life sciences companies, here in Austin.  symBIOsis is open to the broad life sciences community in Austin, with hopes that technology entrepreneurs; UT-Austin graduate students, postdoctoral fellows and faculty; company executives; and others will participate and benefit. 

The kick-off symBIOsis event was held on Tuesday, September 22, from 5:30-7:30PM at the AT&T Executive Conference Center near UT-Austin’s main campus.  The first hour was full of great conversation, networking, and delicious snacks.  Members of the University of Texas community enjoyed the opportunity to meet members of Austin’s life sciences sector, and vice versa. 

The second hour of the evening featured a panel discussion entitled “From Bench to Boardroom: Commercializing Life Sciences Technology,” with three individuals with very interesting and inspirational career pathways.  All three are wonderful examples of how a PhD in science or engineering can prepare one for all kinds of experiences not only in academia, but also within the life sciences industry. 

The panelists included: 

Thomas Milner, PhD
Marion E. Forsman Centennial Professor in Engineering
Department of Biomedical Engineering, UT-Austin


Bill Williams, PhD
Johnson & Johnson Centennial Professor of Pharmaceutics
Division Head, Pharmaceutics, UT-Austin
Editor-in-chief, Drug Development and Industrial Pharmacy

Matt Winkler, PhD
Chief Executive Officer
Chief Scientific Officer
Asuragen, Inc. 

Jessica Hanover, PhD, Director, ATI-Bioscience, moderated the panel discussion.  The conversation was particularly interesting to the graduate students and academicians in the room, with great insights into different roles for scientists and engineers within life sciences companies, and how academicians like the panelists had been successful transitioning to, or overlapping with, the life sciences industry.

Stay tuned for upcoming plans for symBIOsis in the future – you can check for updates at our website www.symbiosisaustin.org.

Share and Enjoy:
  • E-mail this story to a friend!
  • Print this article!
  • Digg
  • del.icio.us
  • Facebook
  • LinkedIn
  • Twitter

ATI Bioscience Part of Austin-Round Rock Life Sciences Cluster

Monday, September 21st, 2009

The following note was sent by Brian Kelsey, Director, Community & Economic Development at the Capital Area Council of Governments and republished with his permission.

The Austin American-Statesman ran an interesting article today on venture capital activity in the life sciences sector (Biotech industry tries to shrug off setbacks). Definitions vary for what exactly belongs to the life sciences/biotechnology sector, but its footprint in Austin-Round Rock may surprise you. We currently have approximately 1,300 establishments and 52,500 jobs in the life sciences cluster, up from 43,000 jobs in 2002 (22%). Forecasters predict that our life sciences cluster could grow by another 14,000 jobs (27%) by 2019. (Source: EMSI <http://www.economicmodeling.com/> ).
 
Attached Below is a map showing where all these jobs are located by zip code in the Austin-Round Rock region. Hospitals lead the way in this cluster with an estimated 16,500 jobs. On the production side, there are 78 establishments with approximately 3,200 jobs engaged in manufacturing activity.
 
Life sciences—regardless of how you want to define it—can play a critical role in Austin-Round Rock’s future economic development if we understand our region’s competitive advantage and work together to develop the assets that are required for a viable life sciences cluster. Check out the Texas Life Sciences Collaboration Center <http://www.texaslifesciences.com/>  in Georgetown and ATI Bioscience <http://www.ati.utexas.edu/bio2.htm>  to get an idea of what’s possible.

2009-09-21 Life Sciences Jobs Map

Share and Enjoy:
  • E-mail this story to a friend!
  • Print this article!
  • Digg
  • del.icio.us
  • Facebook
  • LinkedIn
  • Twitter